<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00294736</url>
  </required_header>
  <id_info>
    <org_study_id>OSI-774-107</org_study_id>
    <secondary_id>2005-003883-46</secondary_id>
    <nct_id>NCT00294736</nct_id>
  </id_info>
  <brief_title>A Two-Stage Phase 1 Dose Escalation Pharmacokinetic Study of Tarceva in Patients With Stage IIIB/IV Non-small Cell Lung Cancer Who Continue to Smoke After Failure of One or Two Prior Chemotherapy Regimens</brief_title>
  <official_title>A Two-Stage Phase 1 Dose Escalation Pharmacokinetic Study of TarcevaÂ® (Erlotinib) in Patients With Stage IIIB/IV Non-small Cell Lung Cancer Who Continue To Smoke After Failure of One or Two Prior Chemotherapy Regimens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OSI Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, open-label, randomized phase 1 study of escalating doses of Tarceva in&#xD;
      patients with advanced NSCLC who currently smoke.&#xD;
&#xD;
      Part I will establish the maximum tolerated dose (MTD) of Tarceva in current smokers.&#xD;
&#xD;
      In Part II, patients will be randomized 1:1 to two treatment groups: Arm A (Tarceva MTD&#xD;
      established in Part I) and Arm B (150 mg Tarceva daily). Patients in both arms will be&#xD;
      treated for two weeks and then have pharmacokinetic samples collected on day 14. Part II is&#xD;
      open as of Nov-2006.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To establish the MTD of Tarceva in currently smoking patients with stage IIIB/IV NSCLC.</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the survival of currently smoking patients with stage IIIB/IV NSCLC when given Tarceva at the MTD and 150 mg.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>NSCLC</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm A (Tarceva MTD established in Part I)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm B (150 mg Tarceva daily).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tarceva</intervention_name>
    <description>Dose Escalation: 150-350+ mg/day</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed diagnosis of stage IIIB/IV NSCLC;&#xD;
&#xD;
          -  Must have received 1 or 2 prior chemotherapy regimens for advanced NSCLC and now have&#xD;
             progressive disease;&#xD;
&#xD;
          -  Must have recovered from any treatment-related toxicities prior to registration,&#xD;
             except for alopecia, grade 1 fatigue, or grade 1 neurotoxicity;&#xD;
&#xD;
          -  A current cigarette smoker (minimum of 10 cigarettes per day for &gt;= 1 year and have a&#xD;
             positive test for cotinine) despite advice and support to quit;&#xD;
&#xD;
          -  Age &gt;= 18 years;&#xD;
&#xD;
          -  ECOG PS 0-1 and predicted life expectancy &gt;= 12 weeks;&#xD;
&#xD;
          -  Previous surgery is permitted provided that wound healing has occurred prior to&#xD;
             registration;&#xD;
&#xD;
          -  Adequate hematopoietic, hepatic and renal function defined as follows: ANC &gt;= 1.5 x&#xD;
             10^9/L, platelets &gt;= 100 x 10^9/L, bilirubin &lt;= 1.5 x ULN, ALT &lt;= 2.5 x ULN (or 5 x&#xD;
             ULN in case of liver metastases), creatinine &lt;= 1.5 x ULN;&#xD;
&#xD;
          -  No prior treatment with Tarceva or gefitinib (or other drug with significant activity&#xD;
             against EGFR (eg, cetuximab and/or ZD6474));&#xD;
&#xD;
          -  Patients with reproductive potential must practice effective contraceptive measures&#xD;
             throughout the study. Women of child-bearing potential must provide a negative&#xD;
             pregnancy test within 14 days prior to registration;&#xD;
&#xD;
          -  Accessible for repeat dosing and follow-up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any concurrent anticancer cytostatic or cytotoxic chemotherapy;&#xD;
&#xD;
          -  Concomitant CYP3A4 or CYP1A2 inducers/inhibitors (or during 14 days prior to study)&#xD;
             with the exception of tobacco;&#xD;
&#xD;
          -  Other active malignancies, unless disease-free and without cancer-specific therapy for&#xD;
             at least the last 5 years. Basal or squamous cell skin cancers are not excluded;&#xD;
&#xD;
          -  Significant history of cardiac disease unless the disease is well-controlled;&#xD;
&#xD;
          -  Active or uncontrolled infections or serious illnesses or medical conditions that&#xD;
             could interfere with the patient's ongoing participation in the study;&#xD;
&#xD;
          -  History of any psychiatric condition that might impair the patient's ability to&#xD;
             understand or comply with the requirements; of the study or to provide informed&#xD;
             consent.&#xD;
&#xD;
          -  Gastrointestinal abnormalities, including inability to take oral medication,&#xD;
             requirement for IV alimentation, active peptic ulcer or prior surgical procedures&#xD;
             affecting absorption;&#xD;
&#xD;
          -  Clinically significant ophthalmologic abnormalities;&#xD;
&#xD;
          -  Pregnant or breast-feeding females. Males or females not practicing effective birth&#xD;
             control;&#xD;
&#xD;
          -  Symptomatic brain metastases which are not stable, require steroids, or that have&#xD;
             required radiation within the last 28 days;&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to the study drug;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>OSI Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Comprehensive Blood and Cancer Center</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Comprehensive Cancer Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Edinburgh,Division of Oncology,</name>
      <address>
        <city>Edinburgh</city>
        <state>Scotland</state>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aberdeen Royal Infirmary</name>
      <address>
        <city>Aberdeen</city>
        <zip>AB25 2ZN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ninewells Hospital</name>
      <address>
        <city>Dundee</city>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beatson West of Scotland Cancer Centre</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Bobby Robson Cancer Trials Research Centre</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE7 7DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Oncology</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital</name>
      <address>
        <city>Sutton</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <study_first_submitted>February 17, 2006</study_first_submitted>
  <study_first_submitted_qc>February 17, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2006</study_first_posted>
  <last_update_submitted>August 6, 2012</last_update_submitted>
  <last_update_submitted_qc>August 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 8, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lung cancer</keyword>
  <keyword>erlotinib</keyword>
  <keyword>NSCLC</keyword>
  <keyword>smokers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

